References
- Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79:8–15.
- Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk of coronary events. N Engl J Med. 2007;357:2109–2122.
- Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089–2099.
- Lincoff AM, Nicholls SJ, Riesmeyer JS, et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med. 2017;376:1933–1942.
- Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363:2406–2415.
- Kastelein JJ, Besseling J, Shah S, et al. Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholestrolaemia (REALISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet. 2015;385:2153–2161.
- HPS3/TIMI55-REVEAL Collaboration Group. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Eng J Med. 2017;377:1217–1227.
- Merck.com. Merck provides update on anacetrapib development program. [ Cited 2018 Feb 8]. http://investors.merck.com/news/press-release-details/2017/Merck-Provides-Update-on-Anacetrapib-Development-Program/default.aspx
- Gotto AM, Cannon CP, Li XS, et al. Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease. Am J Cardiol. 2014;113:76–83.
- de Vera M, Bhole V, Burns LC, et al. Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review. Br J Clin Pharmacol. 2014;78:684–698.
- Nomura A, Won HH, Khera AV, et al. Protein-truncating variants at the cholesteryl ester transfer protein gene and risk for coronary heart disease. Circ Res. 2017;121:81–88.
- Hovingh GK, Ray KK, Boekholdt SM. Is cholesteryl ester transfer protein inhibition an effective strategy to reduce cardiovascular risk? CETP as a target to lower CVD risk: suspension of disbelief. Circulation. 2015;132:433440.
- Frikke-Schmidt R, Nordestgaard BG, Stene MC, et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA. 2008;299:2524–2532.
- Voight B, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet. 2012;380:572–580.
- Keene D, Price C, Shun-Shin MJ, et al. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitor: meta-analysis of randomised controlled trials including 117,441 patients. Bmj. 2014;349:g4379.
- Masen CM, Varbo A, Nordestgaard BG. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in mean and women: two prospective cohort studies. Eur Heart J. 2017;38:2478–2486.
- van der Tuin SJ, Kühnast S, Berbée JF, et al. Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9. J Lipid Res. 2015;56:2085–2093.
- Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–1722.
- Rios FJ, Lopes RA, Neves KB, et al. Off-target vascular effects of cholesteryl ester transfer protein inhibitors involve redox-sensitive and signal transducer and activation of transcription 3-dependent pathways. J Pharmacol Exp Ther. 2016;357:415–422.
- Simic B, Mocharia P, Crucet M, et al. Anacetrapib, but not evacetrapib, impairs endothelium function in CETP-transgenic mice in spite of marked HDL-C increase. Atherosclerosis. 2017;257:186–194.
- Adis. Obicetrapib – Amgen. [ Cited 2018 Feb 12]. http://adisinsight.springer.com/drugs/800029292